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Abstract 
 
EFFECT OF TUMOR NECROSIS FACTORα  
ON EXPRESSION OF HEME OXYGENASE-1  
IN HUMAN GINGIVAL FIBROBLASTS 
Jay Patel 
 
MS in Biomedical Sciences, September 2014 
Department of Biomedical Sciences 
Philadelphia College of Osteopathic Medicine, Philadelphia, PA 
 
Ruth C.  Borghaei, Thesis Advisor 
 
Periodontitis is a chronic inflammatory disease that is characterized by 
activation of gingival fibroblasts to produce matrix metalloproteinases and other 
inflammatory mediators that contribute to destruction of tissues surrounding the 
teeth.  In the United States, 22% of adults have a mild form of periodontal disease 
and 13% suffer from a severe form of the disease.  In addition to tooth loss, 
periodontitis is associated with increased risk of several conditions, including 
diabetes, osteoporosis, rheumatoid arthritis and cardiovascular disease.  Heme 
oxygenase-1 (HO-1) is activated by a wide variety of stressful stimuli and levels are 
increased in inflamed tissues.  HO-1 degrades free heme, resulting in 3 products, 
biliverdin (which is quickly converted to bilirubin), iron and carbon monoxide (CO).  
  iv 
These products all have antioxidant and anti-inflammatory effects, and HO-1 
appears to have an important role in the resolution of inflammation.  However, 
increased expression of HO-1 in certain tumors is associated with increased 
angiogenesis, metastasis and tumor progression, leading to poor prognosis.  It is 
therefore important to understand how expression of HO-1 is controlled under 
various conditions.  A series of experiments were conducted to determine the effect 
of tumor necrosis factor alpha (TNF) on levels of HO-1 mRNA and protein in 
human gingival fibroblasts (HGF) from patients with periodontitis.  Results show 
that HO-1 mRNA and protein levels decreased over 6 hours in the presence of TNF.  
We hypothesized that TNF might decrease HO-1 by increasing levels or activity of 
the transcriptional repressor Bach1.  However, Bach1 mRNA and protein levels did 
not change significantly over 6 hours after treatment with TNF, and binding of 
nuclear factors to the antioxidant response element of the HO-1 promoter remains 
steady after treatment with TNF.  Although HO-1 expression is sometimes 
regulated at the level of mRNA stability, there was no change in the rate of HO-1 
mRNA degradation following treatment with TNF.  Thus, TNF does decrease HO-1 
mRNA and protein expression, however the mechanism of inhibition is still 
unknown. 
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Introduction 
I) Periodontal Disease 
In the United States, 22% of adults have a mild form of periodontal disease and 
13% suffer from periodontitis, a severe form of the illness (Philstrom et al. 2005).  
Periodontal disease is bacterially induced and affects the bone and tissues that 
support a tooth.  It can range from gingivitis, which is the most common form, to the 
most extreme case, periodontitis.  Gingivitis affects 50-90% of adults worldwide and 
is treatable by exercising better oral hygiene.  Left untreated, however, gingivitis can 
lead to periodontitis.   
Patients with periodontitis show increased levels of pro-inflammatory 
cytokines such as interleukin 1 (IL-1), interleukin 6 (IL-6) and TNFα and decreased 
levels of anti-inflammatory cytokines interleukins 4 and 10 (IL-4, IL-10).  The pro-
inflammatory cytokines activate gingival fibroblasts and contribute to tissue 
destruction by increasing production of matrix metalloproteinases (MMPs), leading 
to tissue degradation, and ultimately tooth loss (Thornton et al. 2000). 
Both genetic and environmental host factors contribute to the development 
of chronic inflammation that results in periodontitis.  It begins with bacterial growth 
within the dental plaque surrounding the tooth.  Plaque buildup leads to an increase 
in gram-negative and anaerobic bacteria growth, causing inflammation that results 
in the loss of supportive connective tissue.  Severe periodontitis results in the 
loosening of the tooth from its surrounding tissue and can cause tooth loss 
(Pihlstrom et al. 2005).  In addition to its immediate effects, periodontitis is a 
chronic inflammatory disease that can be linked to other chronic inflammatory 
 
 
 2 
diseases such as rheumatoid arthritis (RA).  Also, common forms of periodontal 
disease have been associated with systemic conditions, including but not limited to 
atherosclerosis, pulmonary disease and diabetes (Stabholz et al. 2010). 
Periodontitis often begins with infection by Porphyromonas gingivalis, 
producing an enzyme, P.  gingivalis peptidyl-arginine deiminase (PPAD).  This 
enzyme converts arginine residues in proteins to citrulline.  This process of 
citrullination contributes to autoimmune responses against citrullated proteins.  
The eventual accumulation of these proteins could lead not only to periodontitis, but 
also to RA (Koziel et al. 2014).  Since periodontal disease is not only contained in the 
oral cavity but has effects throughout the body, it is important to understand the 
mechanisms through which this disease acts systemically.   
Periodontal disease can be linked to the development of diabetes, 
osteoporosis and RA (Stabholz et al. 2010).  In the case of diabetes, the relationship 
with periodontitis appears to be bi-directional.  Patients with poorly controlled 
diabetes (Type 1 or Type 2) are at increased risk of developing periodontitis, and 
successful treatment of periodontitis improves glycemic control in diabetics 
(Pihlstrom et al. 2005).  A study in 179 Japanese over the age of 70 found that those 
suffering from osteopenia also have an increased risk of periodontal attachment 
loss, ultimately leading to tooth loss (Pihlstrom et al. 2005).   
As in RA, periodontitis is characterized by chronic inflammation leading to 
activation of resident fibroblasts, which produce an excess of proteolytic enzymes 
and inflammatory mediators.  Since gingival fibroblasts are easily accessible, they 
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provide a very useful system in which to study the effects of chronic inflammation 
on fibroblasts.  
II) Heme Oxygenase-1 (HO-1) 
HO-1 is a microsomal protein that degrades heme to yield free iron, 
biliverdin and CO.  Biliverdin is quickly converted to bilirubin by biliverdin 
reductase.  HO-1 plays a critical role in two physiological processes.  The first is the 
recycling of iron molecules for erythropoiesis, and the second is the maintenance of 
cellular homeostasis under stressful conditions.  The latter is accomplished mainly 
through the anti-oxidant and signaling properties of the products from the 
catabolism of heme.  Bilirubin and CO are generally considered to be beneficial at 
normal physiological levels due to their anti-oxidant and anti-inflammatory 
properties, and although free iron can have both pro- and anti-oxidant properties, 
the balance is tilted toward beneficial effects by the induction of ferritin.  However, 
all of these products can also become harmful if high levels persist (Paine et al. 
2010).   
Heme Oxygenase Isozymes: 
Cells undergoing stress frequently trigger inflammatory responses, but they 
also induce enzymes, including HO-1, that work together to counteract the 
damaging effects of the stressor and aid in the resolution of inflammation.  Heme 
oxygenase has three isozymes.  HO-1 is an abundant protein found throughout the 
body at low expression levels until stimulated and up-regulated by a wide variety of 
stressful stimuli.  HO-1 is the only inducible form of this protein in the human body.  
Heme oxygenase-2 (HO-2) is a non-inducible form that is constitutively expressed in 
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the brain.  HO-2 has been found, in vivo, to be critical in the prevention of cerebral 
vascular injury after a seizure.  In vitro, it has been found to be protective against 
oxidative stress.  HO-2 deficient mice had an increased susceptibility to oxidative 
injury and chronic inflammatory complications (Chen et al. 2014).  Heme 
oxygenase-3 (HO-3) was first believed to be located in the spleen, liver, thymus, 
prostate, heart, kidney and brain but was only found in rats (McCourbrey et al. 
1997).  It is a poor catalyst in the degradation of heme, so the function of this 
protein is unclear.  HO-3 has a similar amino acid structure to HO-2 (90%).  
McCourbey et al. (1997) found HO-3 mRNA to be expressed at levels similar to HO-2 
in rat tissues.  He also found HO-3 protein was not expressed in rat tissue and did 
not cross-react with HO-1 and HO-2 polyclonal antibodies.  However, Hayashi et al. 
(2004) found that neither the mRNA nor protein was expressed in rat tissue.  
Instead, they identified two related genes, HO-3a/b, and concluded they were 
pseudogenes of HO-2. 
Role of HO-1 in Inflammation:  
HO-1 expression and activity are highly induced by a wide variety of cell 
stress-related stimuli, and its levels are increased in inflamed tissues.  Kobayashi et 
al. (2006) showed that HO-1 was more abundantly expressed in synovial tissue from 
patients with RA as compared to osteoarthritis or non-inflammatory arthritis.  They 
also provided evidence that HO-1 is important in regulating the immune response, 
since inhibition of HO-1 resulted in increased levels of inflammatory cytokines 
(Kobayashi et al. 2006).  Deficiency of HO-1 in a mouse knock-down model caused 
increased susceptibility to renal fibrosis, which was associated with increased 
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inflammation and epithelial-to-mesenchymal transition (Kie et al. 2008).  Other 
studies in HO-1 knockout mice showed increased oxidation and inflammation in 
response to heme in a model of cerebral malaria and a general pro-inflammatory 
shift in cytokine responses (Paine et al. 2010).  This would suggest that without HO-
1 present and active, inflammation would be more likely to occur and persist 
(Kapturczak et al. 2004).   
HO-1 Induction as a Possible Treatment:  
Induced HO-1 can have beneficial effects as an anti-inflammatory agent, 
protecting cells against the cytotoxicity of oxidative stress and cell death.  HO-1 up-
regulation through gene-therapy has been shown to improve post-ischemic blood 
flow in mice in a model involving femoral artery ligation.  This up-regulation was 
also associated with decreased apoptosis as well as the promotion of angiogenesis 
(Jazwa et al. 2012).  In another series of experiments, Issan et al (2014) found that 
HO-1 induction reduced post-ischemic cardiac damage to the diabetic heart, where 
basal levels of HO-1 are low.  When HO-1 is induced in cardiomyocytes, adiponectin 
levels are increased.  Elevated adiponectin levels increase heart endothelial NO 
synthase expression (eNOS) and protein kinase B (AKT) levels, thereby protecting 
cardiomyocytes by increasing their resistance to oxidants.  They also found that the 
increase in AKT activity is essential for cellular protection against hypoxia-induced 
injury (Issan et al. 2014) 
HO-1 Overexpression: 
Despite its clear beneficial effects in the context of inflammation, there is also 
evidence that increased expression of HO-1 can contribute to the progression of 
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certain cancers by increasing angiogenesis, metastasis and chemoresistance.  IL-1, 
IL-6 and TNFα can all up-regulate HO-1 expression as part of a normal inflammatory 
response.  Studies have shown that over-expression of HO-1 increased the 
occurrence of metastatic tumors in the pancreas of mice (Sunamura et al. 2003).   
In addition, it has been shown that a correlation exists between HO-1 
expression and poor prognosis in patients with gliomas, a type of tumor that begins 
in the brain.  Gandini et al. (2013) found that there was a higher HO-1 protein 
expression in gliomas when compared to normal brain cells, and higher expression 
was linked with decreased survival time of the patient (Gandini et al. 2013).  In 
addition to gliomas, high levels of HO-1 expression have been linked to poor 
prognosis and a high metastatic rate in small cell lung cancer (Tsai 2012).  High 
levels of HO-1 are associated with chemoresistance of tumors.  For example, HO-1 
inhibition in neuroblastomas improved the tumor’s sensitivity to therapy; however, 
the opposite occurred when HO-1 was up-regulated, suggesting that this 
upregulation allowed the neuroblastoma to become more chemoresistant (Furfaro 
et al. 2014).   
III) HO-1 Reaction and Products 
The HO-1 reaction breaks down heme and causes the formation of 3 
products: CO, free iron and biliverdin, which normally, when held in low 
concentrations, exercise cytoprotective effects on cells.  However, if concentrations 
are greatly increased, or persist for long periods of time, they can have harmful 
effects on the body (Paine et al. 2010). 
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Heme: 
Heme is the substrate of the HO-1 reaction.  It consists of a tetrapyrrole ring 
with a central iron atom.  As a prosthetic group for hemoglobin and myoglobin, it is 
essential for the transport and storage of oxygen.  Through its incorporation in 
cytochromes, it is important in electron transport and detoxification in the liver.  
However, it is a very reactive molecule and any accumulation of free heme can cause 
oxidative stress and damage to tissues (Paine et al. 2010). 
Carbon Monoxide: 
Although CO is toxic in excess, moderate levels of CO have many 
physiological benefits.  For example, it inhibits platelet aggregation, whilst assisting 
in vasodilation and pro and anti-apoptosis.  The effects of CO are similar to nitric 
oxide (NO) but are less potent.  CO activates of guanylate cyclase (GC), which 
produces guanosine 3,5-cyclic monophosphate (cGMP).  The production of cGMP is 
involved in regulation of vascular tone, gene expression, neurotransmission and 
many other biological processes (Piantadosi et al. 2008).   
CO acts as an anti-proliferative as well.  Through the activation of GC and the 
increased production of cGMP, p38 mitogen activated protein kinase (MAPK) is 
activated (Figure 1).  This activation and even over-expression can permanently 
stop the cell cycle and cause pre-mature senescence (Jozkowicz et al. 2007).  This 
property plays an important role in decreasing extensive cell growth leading to 
cancers in response to oxidative stress.   
CO has anti-inflammatory properties and protects against heat shock and 
cellular stress.  These properties stem from the effect of CO on the MAPK cascade as 
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seen in its anti-proliferative effects.  The cascade can act differently by inhibiting the 
release of inflammatory cytokines TNF and IL-1 (Ghosh et al. 2010).  This anti-
inflammatory effect could potentially be applied therapeutically to models of 
inflammatory diseases including sepsis and asthma (Ryter et al. 2006).   
Free Iron: 
Iron (Fe2+) is released from the tetrapyrrole ring of heme by HO-1.  High 
levels of free iron have cytotoxic pro-oxidant effects due to its ability to catalyze the 
generation of free radicals.  However, at physiological levels these negative effects 
are countered by the induction of an iron efflux pump and ferritin, which stores 
excess iron and has antioxidant properties (Jozkowicz et al. 2007).   
HO-1 has antioxidant effects that inhibit the phosphorylation of p65, a 
subunit of NF-κB, by increasing ferritin.  The increase in the storage of iron caused 
by ferritin decreases the amount of free iron and its pro-oxidant effects.  NF-κB 
dependent anti-apoptotic genes protect a cell from TNF mediated apoptosis.  By 
inhibiting the phosphorylation of p65, the expression of pro-inflammatory genes 
regulated by NF-κB is reduced which supports the cytoprotective effects of HO-1 
(Gozzelino et al. 2010).    
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Figure 1: Schematic of Heme Catabolism and Biological Functions of HO-1 Products 
The activation of heme oxygenase is caused by an increase in oxidative stress.  HO-1 
acts to break down heme to form iron, biliverdin and carbon monoxide (CO).  Free 
iron (Fe2+) increases the production of radicals leading to tissue injury.  It also 
increases expression of ferritin, which functions in protecting tissue.  Iron efflux also 
acts to decrease oxidative stress, functioning in tissue protection.  Bilverdin is 
converted to bilirubin by biliverdin reductase.  These products protect tissue from 
peroxyl radicals and inhibit the complement cascade.  CO activates a cascade that 
protects the tissue from oxidative stress beginning with guanylyl cyclase.  The p38 
MAPK pathway is also activated, inhibiting inflammatory cytokines and enhancing 
anti-inflammatory IL-10 (Jozkowicz et al. 2007). 
 
Biliverdin/Bilirubin: 
Biliverdin is quickly converted to the antioxidant, bilirubin by biliverdin 
reductase (BVR).  Bilirubin has cytoprotective effects against necrosis, a form of cell 
death (Gozzelino et al. 2010).  Necrosis differs from apoptosis in that necrosis is in 
response to external factors such as infections and toxins whereas apoptosis is 
naturally occurring to prevent tumor cell growth.  In endothelial cells, bilirubin 
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suppresses activation of proinflammatory genes vascular cell adhesion molecule 1 
(VCAM-1), monocyte chemotactic protein-1 (MCP-1), and macrophage colony-
stimulating factor (MCSF) and improves vascular relaxation by restoring eNOS 
expression (Kawamura et al. 2005).  Bilirubin has also been shown to protect 
against inflammation in animal models of cardiovascular and intestinal disorders 
and to reduce leukocyte transmigration to areas of inflammation (Paine et al. 2010).  
Regulation of HO-1 Expression: 
HO-1 is induced by many physiological and pathological stimuli.  These 
include heavy metals, heme, endotoxins, hypoxia, cytokines, NO, bacterial 
compounds, growth factors, UV radiation and oxidative stress (Calay et al. 2014).  
The effect of these inducers can be cell-type specific and context-dependent.  For 
example, hypoxia may induce HO-1 through hypoxia-inducible factor 1 (HIF-1) in 
rat aortic vascular smooth muscle cells.  However, this same effect is not seen in rat 
pulmonary vascular smooth muscle cells (Calay et al. 2014).  HO-1 can be activated 
by external stimuli such as those mentioned above or internal stimuli such as 
systemic stress from the spread of infections.  To understand how HO-1 responds to 
these different internal and external stressors, it is important to first understand its 
regulation. 
A microsatellite polymorphism in the HO-1 proximal promoter affects levels 
of HO-1 expressed and is associated with the incidence of a variety of diseases.  The 
level to which HO-1 is expressed is determined in part by the number of guanine-
thymidine (GT) repeats in the HO-1 promoter (Wagener et al. 2008).  For example, 
an individual who has the shorter version of GT repeats (n<25) has increased 
 
 
 11 
induction and expression of HO-1 in response to stress stimuli, and this has a 
protective effect against RA.  Similarly, a longer GT repeat (n>25) is associated with 
increased susceptibility to RA (Rueda et al. 2007).  Although short GT repeats have a 
protective effect against RA, it is also associated with increased risk and/or severity 
of pancreatic cancer, gastric cancer and malignant melanoma (Vahist et al. 2011, 
Sawa et al. 2008, Okamoto et al. 2006).  Therefore, it is important for the body to 
maintain controlled expression of HO-1, through regulation, in order to achieve the 
appropriate balance of products that contribute to its role in resolution of 
inflammation. 
Regulation of HO-1 expression occurs primarily at the transcriptional level.  
Transcriptional regulation is complex and involves multiple transcription factors.  
They allow induction in response to a wide variety of stimuli.  The induction of HO-1 
in response to stress stimuli is mediated through antioxidant response elements 
(AREs), through which transcription is activated by nuclear factor-E2-related factor 
2 (Nrf2).  In the absence of stimulation, Kelch-like ECH-associated protein 1 (Keap1) 
binds Nrf2 and prevents it from binding to the HO-1 promoter.  This Nrf2-Keap1 
protein complex is located in the cytosol of the cell.  Stress stimuli cause the Nrf2-
Keap 1 complex to dissociate and allow Nrf2 to translocate to the nucleus and 
ultimately induce HO-1 (Paine et al. 2010).  In normal or pre-malignant tissues, Nrf2 
activation can prevent cancer initiation and progression.  However, in malignant 
cells, the presence of Nrf2 has the opposite effect and can promote the growth and 
angiogenesis of the cancerous cells (Kansanen et al. 2012).   
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Bach1 is a transcriptional repressor of HO-1 that competes with Nrf2 for 
binding to ARE sequences.  In the basal state of the cell, Bach1 is bound to small Maf 
proteins forming heterodimers.  As seen in Figure 2, the Bach1-Maf heterodimer is 
able to bind to the ARE sequence on the HO-1 promoter (Paine et al. 2010).  The 
binding of Bach1 to the ARE inhibits HO-1 expression.  However, when levels of free 
heme and/or reactive oxygen species increase, Nrf2 is released from Keap1.  Nrf2 is 
then able to translocate to the nucleus, replace Bach1 on the ARE and induce HO-1.  
Heme also binds Bach1 and causes its translocation out of the nucleus, leaving the 
ARE binding site more easily accessible to Nrf2 (Cheng et al. 2013).   
In a recent study, Okita et al (2013) showed that transforming growth factor 
beta (TGFβ) suppressed the activation of HO-1 expression by electrophiles in breast 
cancer cells by increasing mRNA and protein expression of Bach1 and MafK.  Bach1 
and MafK mRNA and protein levels were elevated, and their binding to the ARE was 
increased.  Interestingly, they also found evidence of cooperation between Bach1 
and the Smad transcription factors induced by TGFβ.  Smad 3 was co-
immunoprecipitated with Bach1, and chromatin immunoprecipitation studies 
showed binding of Smad2/3 to the area of the HO-1 promoter that carries the ARE.  
This finding highlights the complex nature of HO-1 regulation through the ARE, and 
raises the possibility that Bach1 levels or activity might be regulated by other 
factors in addition to heme (Okita et al. 2013). 
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Figure 2: Regulation of HO-1 
HO-1 gene expression is regulated mainly by Nrf2 and Bach1.  These two 
transcription factors bind to the antioxidant response element (ARE) on the HO-1 
promoter.  In a cell under normal conditions, Bach1 is bound to the ARE sequence in 
the nucleus and Nrf2 is inhibited in the cytosol by Keap1.  When the cell is affected 
by stress stimuli and/or heme levels increase, Nrf2 dissociates from Keap1 and 
translocates to the nucleus.  Bach1 is removed from the HO-1 promoter, allowing 
Nrf2 to bind and activate HO-1 gene expression (Paine et al. 2010). 
 
In addition to the Nrf2/Bach1/ARE system, HO-1 expression is regulated by 
multiple transcription factors.  Activator protein 1 (AP-1) is a transcriptional factor 
that regulates HO-1 as well as cellular stress responses.  AP-1 has multiple binding 
sites on the HO-1 promoter and has been shown to be responsive to HO-1 inducers 
(Alam et al. 2006).  While studies have shown Nrf2 to be the primary regulator in 
HO-1 activation, AP-1 has been found to be involved in HO-1 induction by arsenite 
and other inflammatory mediators (Alam et al. 2006).   
 Nuclear Factor-κB (NF-κB) is another transcription factor involved in HO-1 
regulation.  In the basal state of a cell, it is held inactive in the cytosol, bound by an 
inhibitory protein (IκB).  Oxidative stimulation or cellular stress signaling causes 
degradation of the inhibitor, releasing NF-κB.  NF-κB translocates to the nucleus 
where it binds DNA and activates NF-κB dependent genes (Na et al. 2006).  NF-κB 
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regulated genes, c-IAP2 and A1, can reestablish the anti-apoptotic effects that CO 
has on endothelial cells when NF-κB is not active (Brouard 2002). 
It was previously found that NO increased the translocation and DNA binding 
of NF-κB, and that led to the identification of an NF-kB binding site on the HO-1 
promoter (Lavrovsky et al. 1994). Li et al. (2009) treated cardiac tissue with 
inducible nitric oxide synthase (iNOS) to determine in what way NF-κB modulates 
cardiac HO-1.  The result was that iNOS gene transfer caused an increase the 
translocation of NF-κB to the nucleus.  They were able to conclude that the up-
regulation of HO-1 was caused by transcriptional activation by an NF-κB dependent 
pathway (Li et al. 2009).   
HO-1 expression can also be regulated at the post-transcriptional level by 
microRNAs that inhibit translation of the mRNA.  Beckman et al. (2011) showed that 
two miRNAs, miR217 and miR377, act directly on the 3’ UTR region of the HO-1 
mRNA.  Both of the miRNAs act together to attenuate protein expression of HO-1 
(Beckman et al. 2011).  In addition, regulatory proteins binding to the 3’ UTR of the 
HO-1 mRNA have been shown to affect mRNA stability.  NO seems to stabilize HO-1 
mRNA as it dramatically increases its half-life.  It does this by increasing the RNA 
binding protein, HuR.  This protein is increased in the cytoplasm after NO treatment 
and is believed to be responsible for the stabilization of HO-1 mRNA (Kuwano et al. 
2009).  In addition to this, the p38 MAPK pathway is also believed to increase the 
half-life of HO-1, however the proteins that cause this stabilization are not known 
(Li et al. 2004).   
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Information about post-translational regulation is limited.  However, Salinas 
et al (2014) showed that Akt, a protein kinase, could mediate phosphorylation of 
HO-1 in vitro and in cultured human cells.  Akt is sometimes referred to as a 
“survival kinase” and is rapidly activated by strong oxidants such as hydrogen 
peroxide.  Active Akt phosphorylated HO-1 at Ser-188 in vitro, and this was 
associated with a modest increase in activity.  The authors speculate that this post-
translational modification might be important in the rapid activation of pre-existing 
HO-1 in response to sudden cell stress (Salinas et al. 2004).   
Cytokine Regulation:  
 Cytokines appear to have a context-dependent role in regulation of HO-1 
expression.  TNFα has been shown to both increase and decrease expression of HO-
1.  HO-1 protein levels were increased by treatment with IL-1β at 6h and TNFα for 
12 hours in synovial fibroblast cultures derived from patients with RA, (Kitamura et 
al. 2011).  In monocytes, TNFα suppressed HO-1 expression by causing the rapid 
decay of mRNA without affecting protein stability, however the mechanism by 
which this occurs is unknown (Kirino et al. 2007).  Inflammatory cytokine IL-1β has 
been shown to have effects on HO-1 expression similar to TNFα.  IL-1β and TNFα 
increased HO-1 mRNA and protein in normal human keratinocytes (Numata et al. 
2009).  However, in a separate study, IL-1β and TNF were shown to down regulate 
HO-1 in osteoarthritis (OA) chondrocytes.  This may be due to the increase in nitric 
oxide synthase 2 (NOS-2) in the cartilage in response to TNF  (Fernandez et al. 
2003).   
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In contrast, Kirino et al. (2007) showed that TNFα had a different effect on 
HO-1 expression in human peripheral blood monocytes from patients with RA.  
Their study showed that TNFα decreased HO-1 expression and that this decreased 
expression may increase the development of inflammatory responses, such as the 
release of TNFα.  It was also observed that the decrease in HO-1 expression was 
caused by acceleration in decay of HO -1 mRNA.  TNFα was shown to decrease 
mRNA stability, whilst keeping the protein from degrading (Kirino et al. 2007).   
 
IV) Previous Studies 
Although inflammatory cytokines increase HO-1 expression in some systems, 
they decrease it in others, suggesting that these responses may be determined in a 
cell-type and/or condition-specific way.  Previous results from this laboratory have 
shown that treatment of HGF derived from patients with periodontitis with IL-1 
results in decreased expression of HO-1 mRNA (Madani 2012).   
 
V) Goals and Hypothesis 
The over-all goals of this research were to determine whether the 
suppression of HO-1 expression in HGF by IL-1 could be generalized to other pro-
inflammatory cytokines, and if so, to determine the transcriptional or post-
transcriptional mechanism(s) involved.  Based on a recent publication that showed 
that TGFβ decreased HO-1 expression by increasing levels of the transcriptional 
repressor Bach-1 (Okita et al 2013), we began with the hypothesis that TNFα 
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decreases the expression of HO-1 in HGF by inducing and/or activating the 
transcriptional repressor Bach1. 
Methods 
 
Cell Culture: Human gingival tissue samples were obtained from patients undergoing 
surgical treatment of periodontitis from Kevan S.  Green, D.M.D. and Mohammad 
Shamseddin, D.M.D.  Primary cell cultures of human gingival fibroblasts (HGF) 
cultures were established by enzymatic dispersion.  Gingival tissue was cut into 
small pieces, if necessary and placed in 5mL of Hanks Buffered Saline with 0.1% 
trypsin.  This was incubated with stirring at 37°C for 1 hour.  The remaining pieces 
of tissue were saved for digestion with collagenase, while the 0.1% trypsin solution, 
containing the trypsin-digested tissue, was transferred to a centrifuge tube and 
centrifuged at 100 x g (1000 rpm), for 5 minutes.  The supernatant was discarded 
and the pellet, containing digested tissue/cells, was resuspended in 5mL Eagles 
Minimal Essential Medium (EMEM), supplemented with 10% Fetal Bovine Serum 
(FBS), AB/AM (penicillin, streptomycin, amphotericin; Invitrogen, Carlsbad, CA) and 
plasmocin (25μg/ml; Invitrogen, Carlsbad, CA).  A 5mL solution of 1% Collagenase 
in Hanks Buffered Saline was added to the tissue that was not digested with trypsin, 
and this was incubated with stirring at 37°C for 1 hour.  The supernatant was 
transferred to a centrifuge tube and centrifuged for 5 minutes at 100 x g.  The 
supernatant was discarded and the pellet was resuspended in 5mL of EMEM, 
supplemented with 10% FBS, AB/AM and plasmocin (25μg/ml).  The two treated 
solutions, collagenase and trypsin, were combined and plated in a T-25 flask, which 
was then incubated at 37°C.  The EMEM was changed the next day.  Cells were 
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maintained in EMEM supplemented with 10%FBS, AB/AM and plasmocin 
(25μg/ml) and passaged 3-5 times before being used for experiments.  Cells were 
serum deprived overnight before the addition of TNFα (10ng/ml). 
 
RNA isolation: Human gingival fibroblasts were left untreated or treated with TNFα 
(10ng/mL) for up to 6 hours.  After the treatment period, total RNA was isolated 
using the RNeasy Plus Micro Handbook 2011 protocol (Qiagen).  First, media was 
aspirated from the plate and Dulbecco’s Phopshate Buffered Saline (DPBS) was 
added to wash the cells.  After removal of DPBS, 750µL Buffer RLT Plus was added 
directly to each plate to lyse the cells.  Plates were then scraped and the lysate was 
collected in a 1.0mL syringe.  The cell lysate was passed through the 25-gauge 
needle 7 times to further lyse the cells.  The cell lysate was transferred to an 
Eppendorf tube.  Then, 350µL of lysate was transferred to a gDNA Eliminator spin 
column placed in a 2mL collection tube and centrifuged for 1 minute at  8000 x g 
(10,000rpm) in an Eppendorf centrifuge 5424 (Germany).  The column was 
discarded and 350µL of 70% ethanol was added to the flow-through and mixed by 
pipetting.  This mixture was then transferred to an RNeasy MinElute spin column 
also placed in a 2mL collection tube and centrifuged for 15 seconds at 8000 x g.  
After discarding the flow-through, 700µL of Buffer RW1 was added to the RNeasy 
MinElute spin column and centrifuged for 15 seconds at 8000 x g.  After discarding 
the flow through, 500µL of Buffer RPE was added to the RNeasy MinElute spin 
column and centrifuged for 15 seconds at 8000 x g.  After discarding the flow 
through, 500µL of 80% ethanol, made with RNase-free water, was added to the 
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RNeasy MinElute spin column and centrifuged for 2 minutes at 8000 x g.  The 
collection tube was then discarded along with the flow through.  The RNeasy 
MinElute spin column was placed in a new 2mL collection tube and centrifuged for 5 
minutes at 8000 x g with the lid of the column open to dry the membrane.  After 
centrifugation, the collection tube was discarded.  The RNeasy MinElute spin column 
was placed in a 1.5mL collection tube.  Lastly, 14µL of RNase-free water was placed 
directly on the center of the spin column membrane and the column was centrifuged 
for 1 minute at 8000 x g to elute the RNA.   
 
Spectrophotometer Analysis: After the RNA was isolated, it was necessary to verify 
the purification process and quantify the results.  This was done using a Nano Drop 
spectrophotometer (Thermo Scientific).  Two µL of each sample was measured at 
260nm and 280nm.  The purity of each sample was determined by the ratio of the 
wavelengths, 260nm/280nm.  Ratios ranging from 1.9-2.1 were accepted.  The 
nucleic concentration of RNA ranged from 0.02µg/µL-1.0µg/µL. 
 
cDNA synthesis and RT-PCR: RNA was converted to cDNA using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA).  For each 
experiment, equal amounts of RNA (0.2-2.0µg) from each HGF sample, were mixed 
with RNase-free water to total 20µL.  This was then added to the following, to total 
100µL: 51µL of reagent grade deionized distilled water (RGDD), 5µL of MultiScribe 
Reverse Transcriptase, 10µL of RT Buffer, 10µL of Random Primers and 4µL of 
Deoxyribonucleotide Triphosphate (dNTP) Mix (100mM).  cDNA was synthesized 
 
 
 20 
using the Thermocycler T-3000 (25°C for 10 minutes, 37°C for 120 minutes).  Real 
time polymerase chain reaction (RT-PCR) analysis was done using the Applied 
Biosystems 7000 Sequence Detection System.  In a 96-well plate, reactions were 
done in triplicate and the results were normalized to Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH).  Samples were plated in the following manner; 16µL of 
Premix Ex Taq™ Master Mix (TAKARA, Madison, WI) were combined 10µL of RGDD 
and 0.64µL of ROX reference dye (TAKARA, Madison, WI) in each well.  Then 0.56µL 
of probes GAPDH, Heme Oxygenase-1 and Bach1 (Applied Biosystems) were added, 
followed by 2µL of cDNA.  After plating the samples, real-time PCR was performed 
using the Applied Biosystems 7000 Sequence Detection System (95°C for 1 cycle of 
30 seconds, 95°C for 40 cycles of 5 seconds, 60°C for 40 cycles of 37 seconds).  The 
2-CT method was used to evaluate the fold change in gene expression of the given 
probes in reference to the untreated control at time 0, normalized to GAPDH.  
Statistical anaylsis was determined using t-test, one way ANOVA and post hoc Tukey 
test using Microsoft Excel. 
 
mRNA Stability: Human gingival fibroblasts were left untreated or treated with 
TNFα (10ng/mL) for 6 hours.  After treatment, all cultures were treated with 
actinomycin D (5ug/ml).  Cells were harvested at 0, 2, 3 4 and 6 hours after addition 
of actinomycin D.  After RNA isolation, purification and cDNA synthesis, RT-PCR was 
performed using the Applied Biosystems 7000 Sequence Detection System as 
described above to determine levels of HO-1 mRNA.  The half-life of HO-1 mRNA in 
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cells treated with TNFα was estimated by linear regression and compared to the 
half-life in cells not treated with TNFα.   
 
Western Blotting: Human gingival fibroblast cultures were left untreated or treated 
with TNFα (10ng/mL) for up to 6 hours.  Whole cell extraction was accomplished by 
first aspirating cell media from the plates.  Then 2mL of trypsin was added to each 
plate and incubated for 1 minute at 37°C.  Ten mL of sterile DPBS was then added to 
each plate to stop the trypsin reaction.  The cells were then transferred to a 15mL 
centrifuge tube and centrifuged at 400 x g (4000rpm) for 10 minutes at 4°C.  The 
media was then removed and the cell pellet was resuspended in 100µL of RIPA 
buffer.  One mL RIPA buffer solution consists of 50uL 1M Tris-Cl, 30uL 5M NaCl, 
10uL NP40, 50uL DOC, 1uL 1mM DTT, 10uL 0.5mM PMSF, 5uL PIC and 835uL 
RGDD.  The tubes were centrifuged at 14,000rpm for 30 minutes at 4°C.  The 
supernatant was transferred to a separate Eppendorf tube and the cell pellet was 
discarded.  Protein was quantified using the Microplate BCA Protein Assay Kit 
(Thermo Scientific).  Serially diluted Bovine Serum Albumin was used to prepare 
standards.  Compatibility reagent (Thermo Scientific) was diluted using equal parts 
of reconstitution buffer (Thermo Scientific) and RGDD.  Nine μL of standards or 
samples were loaded in duplicate into wells.  Four μL of compatibility reagent was 
added to standards and samples, then the plate was covered and incubated for 15 
minutes at 37°C.  Working reagent was prepared by mixing 50 parts of reagent A to 
1 part reagent B and 260µL was pipetted into each well (a 50:1 ratio with the 
sample).  The plate was covered and incubated for an additional 30 minutes at 37°C.  
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After the plate had reached room temperature, the absorbance of the sample was 
measured at 570nm.  A standard curve was plotted using the standards and the 
concentrations of each sample were determined.  Using the concentrations found 
from the BCA assay, the volume of protein needed to equal 40µg of protein was 
calculated.  This calculated volume was added to RGDD to equal a 10µL 
RGDD/protein mix.  Ten μL of 2x SDS was added to this mixture and denatured 
using a thermocycler for 5 minutes at 95°C.  The samples were then loaded into a 
10% separating, 4% stacking SDS-polyacrylamide gel.  The gel was placed in a 
solution containing 900mL of distilled water and 10mL of 10x Tris/Glycine/SDS 
Buffer (Bio-Rad, Hercules, CA).  The gel ran for 45 minutes to an hour at 125V and 
70 milliamps.  The protein in the polyacrylamide gel was then transferred to 
nitrocellulose using the iBlot Gel Transfer Stocks Nitrocellulose, Mini (Life 
Technologies).  The gel was placed on the nitrocellulose and placed in the iBlot 
Invitrogen (Ethrog Biotechnologies Ltd.; Carlsbad, CA) for 7 minutes.  To stain the 
nitrocellulose, Thermo Scientific Pierce Reversible Protein Stain Kit was used.  The 
stained membrane was blocked with 5mL of antibody diluent (Thermo Scientific) 
for 10 mins.  Ten µL of monoclonal mouse heme oxygenase 1 antibody (A-3; Santa 
Cruz Biotechnology, Dallas, TX) or Bach1 (F-9) and β-tubulin (37; as a normalizer) at 
a concentration of 200µg/mL, were added to the diluent and placed on a rocker for 
one hour.  After pouring off the solution, 5mL of antibody diluent (Thermo Scientific 
Pierce Fast Western Blot Kit; Rockland, IL), 500µL of Fast Western Optimized HRP 
reagent (Thermo Scientific) and 0.42µL secondary Precision Protein Streptactin-
HRP Conjugate (Bio-Rad) were added to the blot and placed on a rocker for 15 
 
 
 23 
minutes.  The blot was then washed 3 times for 5 minutes with 5mL of 1x Fast 
Western wash buffer (Thermo Scientific).  The western blots were visualized using 
Clarity Western ECL Substrate and placed in the VersaDoc Imaging System (Bio-
Rad).  After reading the blot for antibodies HO-1 and/or Bach1, 5mL of antibody 
diluent and 1µL of primary antibody to β-tubulin (37; Santa Cruz Biotechnology, 
Dallas, TX) were added to the blot and placed on a rocker for one hour.  After one 
hour, the solution was poured off, 5mL of antibody diluent and 500µL of Fast 
Western Optimized HRP reagent were added and placed on a rocker for 15 minutes.  
The blot was then washed and visualized as described above.  β-tubulin was used as 
the normalizer for protein loading. 
 
Electrophoretic Mobility Shift Assay (EMSA): Human gingival fibroblast cultures were 
left untreated or treated with TNFα (10ng/mL) for up to 6 hours.  Nuclear extracts 
were isolated by the method of Screiber et al (1989). The supernatant was 
discarded and cell pellet was resuspended in 400μL of Buffer A.  A 10mL solution of 
Buffer A consists of 9.8mL RGDD, 100μL 1M Hepes-OH (pH7.9), 100μL 1M KCl, 4μL 
250mM EDTA, 4μL 250mM EGTA, 10μL 1M DTT, 33μL 0.15M PMSF and 1μL 
5mg/mL Leupeptin.  The suspended pellet was then allowed to swell on ice for 15 
minutes.  Twenty-five μL of 10% Nonidet P-40 (Fluka Analytical) was added to the 
solution and vortexed for 10 seconds.  The solution was centrifuged at 4000 x g for 
30 seconds, then the supernatant (cytosol) was removed and stored at -80°C.  The 
remaining pellet was resuspended in 50μL of Buffer C and centrifuged at 4°C for 5 
minutes at 10000 x g.  A 10mL solution of Buffer C consists of 7.9mL RGDD, 1.0mL 
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10% Glycerol, 200μL 1M Hepes-OH (pH7.9), 800μL 5M NaCl, 40μL 250mM EDTA, 
40μL 250mM EGTA, 10μL 1M DTT, 66μL 0.15M PMSF and 1μL 5mg/mL Leupeptin.  
The supernatant (nuclear extract) was removed and transferred to a new eppendorf 
tube.  The protein concentration was determined as described above.  Protein 
samples were stored at -80°C.   
Synthetic oligonucleotides corresponding to the ARE in the HO-1 promoter 
(Invitrogen), 5’-GATTTTGCTGAGTCACCAGTGCCTCCTCAG-3’ and 5’-
CTGAGGCACTGGTGACTCAGCAAAATC-3’ were annealed for 10 minutes at 60°C in 
reactions containing 30μL TE Buffer, 4μL of oligonucleotides A+B, and 2μL 5M NaCl.  
Three μL annealed probe was combined with 10μg nuclear extract, 2μL 10x binding 
solution, 2μL dI-dC and RGDD to bring volume to 20μL.  This mixture swelled on ice 
for 30 minutes.  Four μL of 6x EMSA gel loading solution (Life Technologies; Eugene, 
OR) was added to each sample before running the gel.  The gel was run in 
Tris/Glycine Buffer (Bio-Rad, Hercules, CA) at 250volts for 5 mins and 200volts for 
40 mins at 75 amps.  The gel was removed after running and washed with 50mL of 
1x TBE and 5μL of SYBR Green EMSA nucleic acid gel stain (Life Technologies).  The 
gel was then washed three times with distilled water.  The gel was visualized using 
the VersaDoc Imaging System (Bio-Rad).  For supershift experiments, a 
concentrated antibody (200µg/0.1mL) was added prior to adding the annealed 
probe to the solution containing protein.  Ten μg nuclear extract, 2μL 10x binding 
solution, 2μL dI-dC and RGDD to bring volume to 20μL were added to 1.5 μL of 
concentrated antibody (Bach1, Nrf2; Santa Cruz Biotechnology).  This mixture 
incubated at room temperature for 30 minutes.  Three μL annealed probe was then 
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added to the mixture and swelled on ice for 30 minutes.  Four μL of 6x EMSA gel 
loading solution (Life Technologies; Eugene, OR) was added to each sample before 
running the gel.  The gel was run and visualized using VersaDoc Imaging System as 
described earlier.   
Results 
 
Effect of TNFα on HO-1 Expression: 
 In order to determine the effects of TNFα on HO-1 expression, HGF cell 
cultures were serum deprived overnight before being treated with TNFα (10ng/mL) 
for up to 6 hours.  HO-1 mRNA expression was quantified by RT-PCR and results 
were normalized to levels of GAPDH mRNA. 
 Analysis of the RT-PCR (Figure 3A) shows that HO-1 mRNA expression was 
decreased by treatment with TNFα in all six HGF cell lines tested, which were 
derived from 6 different individuals with periodontitis.  On average, there was about 
a 40% decrease in expression after 6 hours, which is statistically significant as 
determined by one-way ANOVA with post-hoc Tukey test (P<0.05).   
 Analysis of HO-1 protein levels (Figure 3B) also showed a decrease in HO-1 
levels after cells were treated with TNFα.  This decrease in expression is shown 
beginning at 3 hours and further decreasing at 6 hours.  There was a slight variation 
when comparing the 3-hour time points between mRNA expression and protein 
levels.  It seems in HGF7, there was an increase in HO-1 mRNA expression after 3 
hours, however none of the protein levels show an increase after treatment with 
TNFα.   
 
 
 
 26 
A. 
 
 
 
B. 
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Figure 3: Effect of TNFα on HO-1 Expression. 
HGF cell cultures were untreated or treated with 10ng/mL of TNFα for 3 or 6 hours before isolation of RNA and 
protein.  A) HO-1 mRNA was quantified by real-time PCR in six different cell cultures derived from six patients 
with periodontitis.  Results were normalized to GAPDH mRNA and expressed relative to untreated controls.  as 
the graph shows mean +/-SEM.  Statistical significance was determined by One way ANOVA and Tukey post-hoc 
test.  * p< 0.05 B) Forty μg whole cell lysates from HGF cultures were separated on 10% separating, 4% stacking 
SDS-PAGE.  Immunoblotting was performed using antibodies directed against HO-1 and β-tubulin.  The blot 
shown is representative of four different experiments.  C) Quantification of western blots showing expression of 
HO-1.  Average of HO-1 expression was normalized to internal control β-tubulin.  Statistically significant 
determined by t-test * p< 0.05. 
 
Effect of TNFα on Bach1 Expression: 
 RNA from the same HGF cultures described in Figure 3 was used to analyze 
expression of Bach1 in response to TNFα.  As shown in Figure 4A, results were 
variable, with 4 of 7 cultures showing increased expression of Bach1 following TNFα 
treatment, and 3 showing slightly decreased expression.  On average, there was a 
trend toward slightly increased expression (1.5 fold), with no statistical significance.   
 Analysis of Bach1 protein levels, in two HGF cultures, HGF 102 and 107 (RNA 
not isolated; Figure 4B), showed a decrease in Bach1 protein levels after cells were 
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treated with TNFα.  However, after quantifying the protein with respect to the 
internal control, β-tubulin, there was no significant decrease in Bach1 expression 
(Fig.  5C).   
A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. 
 
 
 
B. 
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Figure 4: Effect of TNFα on Bach1 Expression 
 HGF cell cultures derived from samples from six different individuals were untreated or treated with 
10ng/mL of TNFα for 3 or 6 hours before isolation of total RNA.  A) Bach1 mRNA was quantified by real time 
PCR.  Results were normalized to levels of GAPDH mRNA and expressed relative to untreated controls.  The 
graph shows mean +/- SEM.  B) Forty μg whole cell lysate from HGF 102 were separated on 10% separating, 4% 
stacking SDS-PAGE.  Immunoblotting was performed using antibodies directed against Bach1 and β-tubulin.  A 
similar result was obtained with HGF 107.  C) Quantification of western blots showing expression of Bach1.  
Average of Bach1 expression was normalized to internal control β-tubulin. 
 
Effect of TNFα on HO-1 mRNA Stability 
In order to determine the effects of TNFα on HO-1mRNA stability, HGF cell 
cultures were serum deprived overnight before being treated or untreated with 
TNFα (10ng/mL) for 6 hours and then treated with 5μg/mL of Actinomycin D for 0-
6 hours before isolation of RNA.  HO-1 mRNA expression was quantified by RT-PCR 
and results were normalized to levels of GAPDH mRNA.  
In figure 5B, the half-life of HO-1 in cells without the treatment of TNFα, but 
with actinomycin D is estimated by linear regression to be 2.18 hours.  The half-life 
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of HO-1 in cells with both treatments of TNFα and actinomycin D is 2.22 hours.  The 
correlation coefficients  shown in Figure 5B (0.85 and 0.82) are slightly lower than 
expected.  In Figure 5A, to the analysis was limited to the first 4 hrs after addition of 
actinomycin D.   This resulted in higher correlation coefficients (0.93 and 0.96).  In 
control cultures, the half-life of HO-1 is 2.01 hours.  The half-life of HO-1 in cells 
treated with TNFα is 2.07 hours.  Thus, there is no evidence to suggest that 
decreased levels of HO-1 mRNA following treatment with TNFα are due to 
decreased mRNA stability. 
A. 
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Figure 5: Effect of TNFα on HO-1 mRNA Stability 
HGF cell cultures derived from samples from four different individuals were left untreated or treated with 
10ng/mL of TNFα for 6 hours.  A) The cell cultures were treated with 5μg/mL of transcription inhibitor 
actinomycin D for 0-4 hours.  RNA was isolated 0, 2, 3 and 4 hours after initial treatment with actinomycin D.  B) 
The cell cultures were treated with 5μg/mL of transcription inhibitor actinomycin D for 0-6 hours.  RNA was 
isolated 0, 2, 3, 4 and 6 hours after initial treatment with actinomycin D.  HO-1 mRNA was quantified by real-
time PCR.  Results were normalized to levels of GAPDH mRNA and expressed relative to untreated controls.  The 
graph shows mean +/- SEM with linear regression by Excel. 
 
Effect of TNFα on Binding to ARE in the HO-1 Promoter  
  
 HGF cell cultures were serum deprived overnight before being treated or 
untreated with TNFα (10ng/mL) for 6 hours.  Nuclear extract was isolated to 
determine the binding to the ARE sequence on the HO-1 promoter.   
Analysis of the EMSA showed binding had occurred to the promoter at the 
ARE sequence and did not change for 6 hours after treatment with TNFα treatment 
(Fig.  6A).   
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 A supershift assay was conducted using the same nuclear extract shown in 
the initial EMSA.  Concentrated antibodies directed against Bach1 and Nrf2 were 
added to the binding reactions.   The Bach1 antibody had no obvious effect on 
binding of nuclear proteins to the HO-1 ARE. There did appear to be decreased 
binding in the presence of Nrf2 antibody, but there was no supershift with either 
antibody.   
A.       B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Effect of TNFα on Binding to HO-1 Promoter  
HGF cell cultures derived from samples from one individual were left untreated or treated with 10ng/mL of 
TNFα for 6 hours before isolation of nuclear extract.  A) Ten μg of nuclear extract was isolated and incubated 
with double stranded DNA probe labeled specifically for HO-1.  The mixture was then subjected to 4% non-
dentauring-PAGE.  B) Ten μg of nuclear extract was isolated and incubated with double stranded DNA probe 
labeled specifically for HO-1.  Immunoblotting was performed using concentrated antibodies directed against 
Bach1 and Nrf2.   
 
Discussion 
The experiments in this study have shown that treatment of HGF cultures 
with TNFα results in decreased expression of HO-1 mRNA and protein.  A study by 
Okita et al (2013) showed that TGFβ caused a decrease in HO-1 expression in breast 
cancer cells by increasing the expression of the transcriptional repressor Bach1.  
The current data, however, suggests that a different mechanism is involved in TNFα- 
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mediated inhibition of HO-1 expression in HGF.  Specifically, in 7 different HGF 
cultures, the effects of TNFα on Bach1 expression were variable and small.  On 
average, there was a slight increase in the expression of Bach1 mRNA but it did not 
reach statistical significance.  Two HGF cultures showed little change at the protein 
level.  EMSA was performed and revealed binding to the ARE site in the HO-1 
promoter.  However, there was no evidence of a change in the composition of that 
band in response to TNFα.  Additionally, TNFα inhibition of HO-1 did not appear to 
be a result of increased mRNA degradation.  Thus, the data reported here, in 
combination with previous data by Madani (2012), shows conclusively that 
inflammatory cytokines decrease the expression of HO-1 in HGF cultures derived 
from patients with periodontitis, but the mechanism by which this occurs remains 
unknown.   
Periodontitis is a chronic inflammatory disease that is caused by bacterial 
infection and affects the bone and periodontal tissue surrounding the tooth.  Its 
development is associated with increased levels of inflammatory cytokines, leading 
to activation of resident fibroblasts, which then produce inflammatory mediators 
and proteolytic enzymes leading to degradation of tissues supporting the teeth and 
eventual tooth loss (Thornton 2000).  The study of periodontitis is important not 
only because of its direct effects, but also because of its connection to other diseases 
including diabetes, atherosclerosis, osteoporosis and RA (Stabholz et al. 2010).  In 
terms of the role of activated fibroblasts and production of matrix 
metalloproteinases, periodontitis shares many pathological features with RA 
(Stabholz et al. 2010).  Because gingival fibroblasts are more easily obtained than 
 
 
 34 
synovial fibroblasts or cells from other inflammatory disorders, these cells are used 
to model the role of fibroblasts in chronic inflammation.   
HO-1 is induced in a wide variety of cell types by a large number of stressful 
stimuli, and its levels have been shown to be increased in inflamed tissues.  For 
example, HO-1 expression is up-regulated in the joint tissue of patients suffering 
from RA as compared to normal tissue.  This same increase is also seen in patients 
suffering from osteoarthritis (Kobayashi et al. 2006).  HO-1 has the ability to 
regulate the progression of inflammatory diseases through its catabolic reaction 
with heme.  Heme is contained within many proteins and is released when cells 
undergo stress caused by internal or external stimuli.  The products from this 
catabolism are CO, bilirubin and iron, all of which have cyto-protective effects in the 
body (Rueda et al 2007).  
HO-1 has been studied as a potential therapeutic target in chronic 
inflammatory diseases due to its anti-inflammatory/anti-oxidant properties (Ryter 
et al. 2006).  Hsu et al. (2009) showed that simvastatin, which has been known to 
improve established pulmonary hypertension, acts through the induction of HO-1.  
5-aminosalicylic acid (5-ASA) has been shown to increase HO-1 expression in rats 
presenting with colitis.  The elevated HO-1 expression is thought to play a role in the 
increased anti-oxidant and anti-inflammatory effects exerted by 5-ASA (Horváth et 
al. 2008).  In addition, it was found that HO-1 protects against ischemia and 
reperfusion injury and aids the recovery of contractile function in the hearts of 
transgenic mice (Yet et al. 2001).  
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However, as stated earlier, the over-expression of HO-1 could lead to 
increased angiogenesis and stimulation of tumor growth (Sunamura et al. 2013).  
HO-1 overexpression has also been linked with poor prognosis in several cancers, 
such as gliomas.  In gliomas, protein expression of HO-1 was increased in gliomas in 
comparison with normal brain tissue.  This increase was linked to a shorter survival 
time.  Poor prognosis as well as metastasis has also been found in non-small cell 
lung cancer when HO-1 is overexpressed.  It’s been shown that in neuroblastomas, 
overexpression of HO-1 decreases the sensitivity of the tumor to chemotherapy.  If 
there were a way to limit the expression of HO-1, treatment of cancerous tumors 
would be more effective (Furfaro et al 2014).  Thus, expression of HO-1 is controlled 
by multiple mechanisms in order to allow induction to high levels in response to a 
wide variety of stressors, but also to maintain low basal levels under normal 
conditions.   
Pro-inflammatory cytokines TNFα and IL-1 stimulate synovial fibroblasts to 
increase production of cytokines and pro-catabolic enzymes.  These contribute to 
local inflammation as well as bone and cartilage destruction seen in RA (Goff et al. 
2014).  However, studies on the effect of TNF and IL-1 on HO-1 expression have 
provided conflicting results.  For example, Kitamura et al (2011) found that IL-1 
and TNF both increase HO-1 protein levels in synovial fibroblast cultures derived 
from RA patients.  Similarly, Numata et al. (2009) found that these two 
inflammatory cytokines also increase HO-1 mRNA and protein expression in normal 
human keratinocytes.  However, in another study it was seen that IL-1β and TNF 
both down regulate HO-1 in osteoarthritic chondrocytes (Fernandez et al. 2003).  
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Kirino et al (2007) found that TNFα decreased HO-1 expression but the mechanism 
by which this occurs was not determined.  These prior studies focused on cultures 
from various chronic inflammatory diseases.  Previous studies in our laboratory 
have shown that IL-1 decreases levels of HO-1 mRNA in HGF from individuals with 
periodontitis, but the mechanism was not addressed (Madani 2012).  The results of 
this research extend that study to show that TNF also decreases HO-1 mRNA and 
protein expression in HGF. 
The anti-oxidant response element (ARE) in the HO-1 promoter plays a 
major role in transcriptional regulation of HO-1 expression through the Nrf2/Bach1 
system.  HO-1 induction in response to stressful stimuli is dependent upon Nrf2, 
while low basal levels in the absence of stimulation are maintained by the repressor 
Bach1 (Paine et al 2010).  Nrf2 is regulated by pro-oxidant stimuli that cause it to be 
released from its inhibitor, Keap1 and translocated to the nucleus.  In the nucleus, it 
binds to the ARE sequence on the HO-1 promoter and activates HO-1 expression.  In 
addition to activation by pro-oxidant stimuli, Nrf2 can also be inhibited by a stress 
independent pathway involving glycogen synthase kinase (GSK)-3β.  GSK-3β has 
been shown to inhibit activation of the HO-1 promoter through the ARE by 
phosphorylating Nrf2.  Phosphorylation of Nrf2 inhibits its translocation and 
binding to the ARE site, thus preventing activation of HO-1 (Paine et al, 2010; 
Salazar et al. 2006).  Stress stimuli, such as arsenite and hemin, also act by exporting 
Bach1 from the nucleus, allowing basal levels of Nrf2 within the nucleus to bind to 
the ARE site.  These pathways of phosphorylation and translocation may lead to the 
decrease in expression of HO-1 in HGF. 
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It is important to note that the ARE is also found in the promoters of other 
genes that are activated by Nrf2 in response to oxidant stress and repressed by 
Bach1 under basal conditions.  NADPH quinone oxidoreductase-1, Glutathione-S-
transferase, UDP-glucuronyl transferase, and superoxide dismutases all have AREs 
in their promoters (Cho et al. 2006).  Thus HO-1 is induced along with other 
antioxidant enzymes as part of a coordinated cellular response to stress.  
Presumably, these enzymes work together to restore cellular homeostasis, and then 
they are returned to low basal levels through the repressive action of Bach1. 
Studies with human keratinocytes show nuclear export of Bach1 30 minutes 
after stimulus, whereas in human skin fibroblasts, the protein was exported after 12 
hours post-stimulus (Reichard et al 2007; Raval et al 2011).  The intracellular 
accumulation of heme has been shown to inhibit the repression of HO-1 by binding 
to regulatory motifs of the Bach1 protein.  Heme decreases the DNA binding affinity 
of Bach1, allowing Nrf2 to bind to the ARE (Paine et al. 2010).  It was recently found 
that TGFβ decreases HO-1 expression by increasing levels of the transcriptional 
repressor Bach1 in breast cancer cells (Okita et al 2013).  In cells treated with tBHQ 
(an electrophile), expression of HO-1 is activated by Nrf2.  Treatment with TGFβ, 
after tBHQ reduced Nrf2 binding to the ARE, although it did not affect the 
stabilization or nuclear accumulation of the protein.  The displacement of Nrf2 alone 
is not enough to bring about the repression of HO-1.  TGFβ treatment elevated 
expression of Bach1 and MafK, successfully repressing HO-1 expression in breast 
cancer cells (Okita et al 2013).  In addition to the cooperation found between Bach1 
and Smad2/3 proteins, the upregulation of this heterodimer may provide a 
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mechanism by which HO-1 expression can be repressed.  Based on this report, we 
hypothesized that inflammatory cytokines might be repressing expression of HO-1 
in HGF by increasing expression and/or DNA binding of Bach1. 
 
Effect of TNF on the Expression of HO-1: 
 Our results show that TNF causes a significant decrease in HO-1 mRNA and 
protein expression from 3 to 6 hours in HGF.  HO-1 mRNA expression was decreased 
on average by 40% (Figure 3A).  HO-1 protein expression began decreasing at 3 
hours, and continued to decrease up to 6 hours (Figure 3B).  This data is consistent 
with that of Kirino et al. (2007) in human peripheral blood monocytes from patients 
with RA as well as that of Fernandez et al. (2003), who showed that TNF decreased 
expression of HO-1 in chondrocytes.  Kirino et al. (2007) attributed the decrease in 
HO-1 expression to increased mRNA degradation.  There was no evidence to 
indicate that in HGF, the rate of mRNA degradation increased in response to TNF.  
Fernandez et al. (2003) attributed the effect to an increase in NOS-2 and NO levels in 
response to TNF, although the mechanisms involved were not described.  Neither 
of these studies examined the role of the Nrf2/Bach1 system in cytokine regulation 
of HO-1 expression. 
Although we began with the hypothesis that TNF inhibition of HO-1 
expression involved upregulation of Bach1, we found no evidence to support this.  
Bach1 expression in response to TNF was somewhat variable in different HGF 
cultures (Figure 4A).  On average, there was perhaps a trend toward a slight 
increase in Bach1 mRNA in response to TNF at 3 and 6-hour time points, but there 
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was no significant change.  Bach1 protein levels also showed no significant changes 
in response to TNF following normalization with β-tubulin (Figure 4B, 4C).  The 
results of these experiments do not support the hypothesis that TNF inhibits HO-1 
expression by increasing levels of the Bach1 repressor. 
In order to determine whether TNF might alter Bach1 DNA binding activity 
without affecting its levels, EMSA was performed using nuclear extract isolated from 
HGF cultures treated or not with TNF for 6 hours.  There was binding to the ARE 
site from the HO-1 promoter in both control and 6 hour TNF samples, but there 
was no obvious difference in intensity or migration of the band (Fig.  6A).  A 
supershift assay was then performed using the same nuclear extract to determine 
what was binding to the ARE sequence on the promoter (Fig 6B).  Inclusion of Bach1 
and Nrf2 antibodies in the binding reactions failed to shift the mobility of the ARE-
binding protein complex.  However, although binding to the ARE did seem to be 
decreased in the presence of Nrf2 antibody, there was no obvious change in TNF-
treated extract as compared to control.  Thus, there is no evidence to suggest that 
binding to the ARE is altered by TNF treatment. 
Since HO-1 expression is influenced by multiple transcription factors acting 
through sites other than the ARE, it is possible that TNF treatment affects HO-1 
expression by modifying the levels or activity of one or more of these.  Both AP-1 
and NF-B are transcription factors known to participate in HO-1 regulation (Paine 
et al 2010), and to be the subjects of regulation by multiple complex pathways and 
feedback mechanisms.  For example, TNF is known to induce NF-B, but there is a 
complex feedback mechanism between NF-B and human biliverdin reductase 
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(hBVR), which could result in inhibition of HO-1 expression rather than induction.  
Lavrovsky et al. (1994) has shown that there is an NF-B site on the HO-1 promoter 
that may be essential in the up-regulation of HO-1 (Lavrovsky et al. 1994).  hBVR is 
induced by hypoxia and TNF, but is indirectly inhibited by NF-B.  The initial 
expression of TNF activates both NF-B and hBVR.  When hBVR is overexpressed 
by TNF, NF-B is activated.  However, as NF-B is expressed for a long period of 
time, hBVR expression is reduced due to the inhibition of the hBVR promoter by up-
regulated NF-B.  This reduction inhibits the activation of NF-B.  This complex 
feedback system shows that treatment with TNF initially increases hBVR leading 
the activation of NF-B and HO-1.  However as TNF persists, levels of hBVR and 
NF-B are subsequently reduced, ultimately leading to a decrease in HO-1 activity 
(Gibbs et al. 2010).   
mRNA stability depends on the interaction between cis-acting elements and 
trans-acting factors.  Cis-acting elements are comprised of highly conserved primary 
sequences or stable stem-loop structures.  miRNAs and RNA-binding proteins are 
considered trans-acting factors that play a role in regulating mRNA stability 
(Cheneval et al. 2010).  Other studies have also shown that miRNAs can also alter 
the half-life of HO-1 mRNA, but there is no evidence suggesting that TNF modifies 
the expression of these miRNAs (Beckman et al. 2011).  RNA binding protein, HuR, 
has been indicated as a potential stabilizer of mRNA.  HuR assists NO in stabilizing 
HO-1 mRNA in HGF.  Leautaud et al (2010) suggested that NO can increase the 
stability of HO-1 mRNA to 11 hours.  When HuR is silenced, even with NO treatment, 
 
 
 41 
HO-1 mRNA does not seem to be as stable as when HuR is active.  This suggests that 
HuR is needed to increase the half-life of HO-1 (Kuwano et al. 2009).   
An alternative hypothesis is that treatment with TNF decreases HO-1 mRNA 
levels by destabilizing the RNA as suggested by Kirino et al (2007).  HO-1 mRNA has 
been found to have a half-life of 1.6 hours in mouse embryonic fibroblast cells 
(Leautaud et al. 2007).  Interestingly, in the presence of NO, the half-life of this 
enzyme can increase to 11 hours (Kuwano et al. 2009; Leautaud et al. 2007).  Our 
data did not show a difference in stability of HO-1 mRNA in cells treated with TNF 
for 6 hours (2.22 hrs; Figure 5 ) as compared to untreated controls (2.18 hrs).  Since 
the levels of HO-1 mRNA have declined to very low levels after 6 hours with 
actinomycin, an improved correlation coefficient was obtained when the regression 
analysis was limited to 4 hours.  In this case the half-life of HO-1 mRNA is calculated 
as 2.01 hours in untreated cells and 2.07 hours in cells treated for 6 hours with 
TNF before addition of actinomycin.  This is a slightly longer half-life than was 
found by Leautaud et al. (2007), but there is no evidence that treatment of HGF with 
TNF causes decreased HO-1 mRNA stability.   
Conclusion 
 This study was able to determine that HO-1 expression decreased protein 
and mRNA levels in HGF after treatment with TNFα.  However, we were unable to 
confirm previous studies by Okita et al (2013) that have shown a decrease in HO-1 
expression caused by an increase in the repressor Bach1.  Protein binding did occur 
at the ARE sequence on the HO-1 promoter.  However, since there was no change in 
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the mobility of the complex with or without TNFα, there is no evidence to suggest 
that changes in Bach1 or NRF2 interactions with the ARE were responsible for 
decreased expression of HO-1 in TNF treated cells.  There is also no evidence to 
suggest TNFα decreases HO-1 expression by increasing the rate of HO-1 mRNA 
degradation.  Given that the mechanism in which TNFα acts in decreasing HO-1 
expression is still unknown, future experiments should focus on determining how 
HO-1 is decreased.   
The major finding of this study is that TNFα causes decreased expression of 
HO-1 mRNA and protein in HGF cultures derived from patients with periodontitis.  
We further showed that Bach1 mRNA and protein levels, although somewhat 
variable in HGF, were not significantly affected by TNFα.  In addition, we found no 
evidence that binding of Bach1 or Nrf2 to the ARE was affected by TNFα treatment, 
and no evidence that treatment with TNFα altered the stability of HO-1 mRNA.  
Given the important role of HO-1 in regulating cellular responses to inflammation 
and stress, further experiments should be directed at understanding the 
mechanisms involved in maintaining appropriate levels of HO-1. 
Limitations and Future Studies 
 A major limitation to these studies was the variation in expression of Bach1 
observed in HGF cell cultures, which were derived from individual patients with 
periodontitis.  Given the small number of samples used, it is difficult to determine 
how much of the variation observed was due to actual individual differences in the 
cells and how much was experimental variation.  The clinical information received 
about the individual patients was limited.  It also may have been beneficial to have 
 
 
 43 
known what other diseases the patients may be suffering from such as diabetes, 
other systemic diseases or whether the patient was on any medication.  These and 
other types of variation among the patients might have affected basal expression 
levels of HO-1, Bach1 and Nrf2, or the response of the cell cultures to cytokines, such 
as TNF.  It would be interesting to determine whether there is significant variation 
in basal levels of these proteins in the periodontitis-derived tissues, and to attempt 
to correlate differences with clinical parameters such as age, smoking status and 
diabetes.  It would also be interesting to compare the basal levels found in the 
periodontitis-derived HGF cultures with levels in “normal” HGF cultures derived 
from non-inflamed tissue samples.  A more consistent cell culture system would also 
make determination of mechanisms much easier by limiting the potential sources of 
variation.  
  In addition, the methodology used to determine changes in protein binding 
to the ARE could be improved.  In these studies, an EMSA was performed to 
determine is binding to the ARE site was occurring and what specifically was 
binding.  These studies were inconclusive.  Since binding to a short piece of DNA in 
EMSA may not accurately reflect binding to the actual site on endogenous 
chromatin, chromatin immunoprecipitation experiments would have been more 
informative, and could also be used to determine whether there are changes in 
binding of other transcription factors known to interact with the HO-1 promoter..  
Further studies might also address whether the intracellular locations of Bach1, 
Nrf2, or even HO-1 proteins are affected by cytokine treatment.   
 
 
 
 44 
References: 
Alam J, Cook, Julia L.  “How Many Transcription Factors Does it Take to Turn On the 
Heme Oxygenase-1 Gene?” American Journal of Respiratory Cell and Molecular 
Biology.  2006, 36: 166-174.   
 
Barañano, D., Wolosker, H., Bae, B., Barrow, R., Snyder, S., Ferris, C.  “A Mammalian 
Iron ATPase Induced by Iron”.  The Journal of Biological Chemistry.  2000, 275: 
15166-15173. 
 
Beckman, J.  D., Chen, C., Nguyen, J., Thayanithy, V., Subramanian, S., Steer, C.  J., et al. 
“Regulation of heme oxygenase-1 protein expression by miR-377 in 
combination with miR-217”.  The Journal of Biological Chemistry, 2011, 286: 
3194-3202. 
 
Brouard, S., Berberat, P., Tobiasch, E., Seldon, M., Bach, F., Soares, M.  “Heme 
Oxygenase-1-derived Carbon Monoxide Requires the Activation of 
Transcription Factor NF-κB to Protect Endothelial Cells from Tumor Necrosis 
Factor-α-mediated Apoptosis”.  The Journal of Biological Chemistry.  2002, 
277: 17950-17961. 
 
Calay, D., Mason, J.  “The Multifunctional Role and Therapeutic Potential of HO-1 in 
the Vascular Endothelium”.  Antioxidants and Redox Signaling.  2014, 20(11).  
 
 
 
 45 
Chen, R., Yuan, H., Zhang, T., Wang, Z., et al. “Heme Oxygenase-2 Suppress TNF-α and 
IL6 Expression via TLR4/MyD88-Dependent Signaling Pathway in Mouse 
Cerebral Vascular Endothelial Cells”.  Molecular Neurobiology.  2014 May 1.   
  
Cheng, X., Ku, C.H., Siow, R.  “Regulation of the Nrf2 antioxidant pathway by 
microRNAs: New players in micromanaging redox homeostasis”.  Free 
Radical Biology and Medicine.  2013, 64: 4-11. 
 
Cho, H., Reddy, S., Kleeberger, S. “Nrf2 Defends the Lung from Oxidative Stress”. 
Antioxidant and Redox Signaling. 2006, 8:1-2.  
 
Fernandez, P., Guillen, M., Gomar, F., Alcaraz, M.  “Expression of heme oxygenase-1 
and regulation by cytokines in human osteoarthritic chondrocytes”.  
Biochemical Pharmacology.  2003, 66: 2049-2052.   
 
Florcyzk, U., Jozkowicz, A., Dulak, J.  “Biliverdin reductase: new features of an old 
enzyme and its potential therapeutic significance”.  Pharmacological Reports.  
2008, 60: 38-48. 
 
Furfaro AL, Piras S, Passalacqua M, Domenicotti C, Parodi A, Fenoglio D, Pronzato 
MA, Marinari UM, Moretta L, Traverso N, Nitti M.  “HO-1 up-regulation: A key 
point in high-risk neuroblastoma resistance to bortezomib.” Biochim Biophys 
Acta.  2014; 1842(4): 613-22. 
 
 
 46 
Gandini, N., Fermento, M., Salomon, D., Obiol, D., Andres, N., Zenklusen, J., Arevalo, J., 
Blasco, J., Romero, A., Facchinetti, M., Curino, A.  “Heme oxygenase-1 
expression in human gliomas and its correlation with poor prognosis  in 
patients with astrocytoma”.  Tumor Biology.  2014, 35: 2803–2815. 
 
Ghosh, S., Gal, J., Marczin, N.  Carbon monoxide: “Endogenous mediator, potential 
diagnostic and therapeutic target”.  Annals of Medicine.  2010; 42: 1–12. 
 
Gibbs, P., Maines, M.  “Biliverdin inhibits activation of NF-jB: Reversal of inhibition 
by human biliverdin reductase”. International Journal of Cancer.  2007, 121: 
2567–2574. 
 
Goff, B., Singbrant, S., Tonkin, B., Martin, T., Romas, E., Sims, N., Walsh, N.  
“Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in 
synovial fibroblasts”.  Cytokine.  2014, 68: 101–109. 
 
Gozzelino, R., Jeney, R., Soares, M.  “Mechanisms of Cell Protection by Heme 
Oxygenase-1”.  Annual Review of Pharmacology Toxicology.  2010, 50: 323-
354. 
 
Guillen, M., Megias, J., Gomar, F., Alcatraz, M.  “Haem oxygenase-1 regulates catabolic 
and anabolic processes in osteoarthritic chondrocytes”.  Journal of Pathology. 
2008, 214: 515–522. 
 
 
 47 
Hayashi, S., Omata, Y., Sakamoto, H., Higashimoto, Y., Hara, T., Sagara, Y., Noguchi, M.  
Characterization of rat heme oxygenase-3 gene.  “Implication of processed 
pseudogenes derived from heme oxygenase-2 gene”.  Science Direct.  2004, 
241–250. 
 
Hovarth, K., Varga, C., Berko, A., Posa, A., Laszlo, F., Whittle, B.  “The involvement of 
heme oxygenase-1 activity in the therapeutic actions of 5-aminosalicylic acid 
in rat colitis”.  European Journal of Pharmacology.  2008, 583; 3: 315-323. 
 
Hsu, H., Ko, W., Hsu, J., Chen, J., Lee, Y., Lai, I., Chen, C.  “Simvastatin ameliorates 
established pulmonary hypertension through a heme oxygenase-1 
dependent pathway in rats”.  Respiratory Research.  2009, 10: 32. 
 
Issan, H., Kornowski, R., Aravot, D., Shainberg, A., Lanaido, M., Sodhi, K., Abraham, N., 
Hochhauser, E.  “Heme Oxygenase-1 Induction Improves Cardiac Function 
following Myocardial Ischemia by Reducing Oxidative Stress”.  Plos One. 2014, 
9: Issue 3. 
 
Jazwa, A., Stepniewski, J., Zamykal, M., Jagodzinska, J., Meloni, M., Emanueli, C., 
Jozkowicz, A., Dulak, J.  “Pre-emptive hypoxia-regulated HO-1 gene therapy 
improves post-ischaemic limb perfusion and tissue regeneration in mice”.  
Cardiovascular Research.  2013, 97: 115–124. 
 
 
 
 48 
Jozkowicz, A., Was, H., Dulak, J.  “Heme Oxygenase-1 in Tumors: Is It a False Friend?” 
Antioxid Redox Signal. 2007, 9(12): 2099–2117. 
 
Kansanen, E., Kousmanen, S., Leinonen, H., Levonen, A (2012).  “Review Article: The 
Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer”.  
Redox Biology [serial online].  2013, 1: 45-49.  Available from: ScienceDirect, 
Ipswich, MA. 
 
Kapturczak, M., Wasserfall, C., Brusko, T., Thompson, M., Ellis, T., Atkinson, M., 
Agarwal, A.  “Heme Oxygenase-1 Modulates Early Inflammatory Responses: 
Evidence from the Heme Oxygenase-1-Deficient Mouse”.  American Journal of 
Pathology. 2004, 165(3):  1045-1053. 
 
Kawamura, K., Ishikawa, K., Wada, Y., Kimura, S., Matsumoto, H., Kohro, T., Itabe, H., 
Kodama, T., Maruyama, Y.  “Bilirubin From Heme Oxygenase-1 Attenuates 
Vascular Endothelial Activation and Dysfunction”.  Arteriosclerosis 
Thrombosis and Vascular Biology.  2005, 25:155-160. 
 
Kie JH, Kapturczak MH, Traylor A, Agarwal A, Hill-Kapturczak N.  “Heme oxygenase-
1 deficiency promotes epithelial-mesenchymal transition and renal fibrosis”.  
Journal of the American Society of Nephrology.  2008, 19: 1681-1691. 
 
 
 
 
 49 
Kirino, Y., Takeno, M., Murakami, S., Kobayashi, M., Kobayashi, H., Miura, K., Ideguchi, 
H., Ohno, S., Ueda, A., Ishigatsubo, Y.  “Tumor Necrosis Factor  Acceleration 
of Inflammatory Responses by Down-Regulating Heme Oxygenase 1 in 
Human Peripheral Monocytes”.  Arthritis & Rheumatism.  2007, 56(2): 464–
475. 
 
Kitamura, A., Nishida, K., Komiyama, T., Doi, H., Kadota, Y., Yoshida, A., Ozaki, T.  
“Increased level of heme oxygenase-1 in rheumatoid arthritis synovial fluid”.  
Modern Rheumatology.  2011, 21: 150–157. 
 
Kobayashi, H., Takeno, M., Saito, T., Takeda, Y., Kirino, Y., Noyori, K., Hayashi, T., 
Ueda, A., Ishigatsubo, Y.  “Regulatory Role of Heme Oxygenase 1 in 
Inflammation of Rheumatoid Arthritis”.  Arthritis & Rheumatism.  2006, 54(4): 
1132–1142. 
 
Koziel, J., Mydel, P., Potempa, J.  “The Link Between Periodontal Disease and 
Rheumatoid Arthritis: An Updated Review”.  Current Rheumatology. 2014,  
16: 408. 
 
Kuwano, Y., Rabinovic, A., Srikantan, S., Gorospe, M., Demple, B.  “Analysis of Nitric 
Oxide-Stabilized mRNAs in Human Fibroblasts Reveals HuR-Dependent 
Heme Oxygenase 1 Upregulation”.  Molecular and Cellular Biology. 2009, 
29(10): 2622. 
 
 
 50 
Lavrovsky, Y., Schwartzman, M., Levere, R., Kappas, A., Abraham, N.  “Identification 
of binding sites for transcription factors NF-B and AP-2 in the promoter 
region of the human heme oxygenase 1 gene”.  Proceedings of the National 
Academy of the Sciences. 1994, 91: 5987-5991. 
 
Leautaud, V., Demple, B.  “Regulation of heme oxygenase-1 mRNA deadenylation and 
turnover in NIH3T3 cells by nitrosative or alkylation stress”.  BMC Molecular 
Biology. 2007, 8: 116. 
 
Li, L., Julien, B., Grenard, P., Clerc, F., Mallat, A., Lotersztajn, S.  “Molecular 
mechanisms regulating the antifibrogenic protein heme-oxygenase-1 in 
human hepatic myofibroblasts”.  Journal of Hepatology. 2004, 41: 407–413. 
 
Li, Q., Guo, Y., Ou, Q., Cui, C., Wu, W., Tan, W., Zhu, X., Lanceta, L., Sanganalmath, S., 
Dawn, B., Shinmura, K., Rokosh, G., Wang, S., Bolli, R.  “Gene Transfer of 
Inducible Nitric Oxide Synthase Affords Cardioprotection by Upregulating 
Heme Oxygenase-1 Via a Nuclear Factor- κB-Dependent Pathway”.  
Circulation.  2009, 120:1222-1230. 
 
Livak, K., Schmitgen, T.  “Analysis of Relative Gene Expression Data Using Real-Time 
Quantitative PCR and the 2−ΔΔCT Method”.  Methods.  2001, 25(4): 402-408. 
 
 
 
 51 
Madani, S, Borghaei RC.  “Role of Heme Oxygenase-1 in interleukin-1 induced 
expression of matrix metalloproteinase-3 in human gingival fibroblasts.” 
Philadelphia College of Osteopathic Medicine. 2011. 
 
McCoubrey, W., Huang, T., Maines, M.  “Isolation and characterization of a 
cDNA  from the rat brain that encodes hemoprotein heme oxygenase-3”.  
European Journal of Biochemistry.  1997,  247: 725-732. 
 
Na, K., Surh, Y.  “Transcriptional Regulation via Cysteine Thiol Modification: A Novel 
Molecular Strategy for Chemoprevention and Cytoprotection”.  Molecular 
Carcinogenesis.  2006, 45: 368-380. 
 
Numata, I., Okuyama, R., Memezawa, A., Ito, Y., Takeda, K., Furuyama, K., Shibahara, 
S., Aiba, S.  “Functional Expression of Heme Oxygenase-1 in Human 
Differentiated Epidermis and Its Regulation by Cytokines”.  Journal of 
Investigative Dermatology.  2009, 129: 2594–2603. 
 
Okamoto, I., Krogler, J., Endler, G., Kaufmann, S., Mustafa, S., Exner, M., Mannhalter, 
C., Wagner, O., Pehamberger, H.  “A microsatellite polymorphism in the heme 
oxygenase-1 gene promoter is associated with risk for melanoma”.  
International Journal of Cancer.  2000, 119: 1312–1315. 
 
 
 
 52 
Okita Y, Kamoshida A, Hiroyuki S, Itoh K, Motohashi H, Igarashi K, Yamamoto M, 
Ogami T, Koinuma D, Kato M.  “Transforming Growth Factor- Induces 
transcription factors MafK and Bach1 to Suppress Expression of the Heme 
Oxygenase-1 Gene”.  The Journal of Biological Chemistry.  June 4, 2013.   
 
Otterbein, L., Bach, F., Alam, J., Soares, M., Lu, H., Wysk, M., Davis, R., Flavell, R., Choi, 
A.  “Carbon monoxide has anti-inflammatory effects involving the mitogen-
activated protein kinase pathway”.  Nature Medicine.  2000, 6(4): 422-428. 
 
Paine A, Eiz-Vesper B, Blasczyk R, Immenschuh S.  “Signaling to Heme Oxygenase-1 
and its Anti-inflammatory Therapeutic Potential”.  Elsevier [serial online]. 
2010; 1896-1901.  Available from: ScienceDirect, Ipswich, MA. 
 
Perrson, G.  “Rheumatoid arthritis and periodontitis � inflammatory and infectious 
connections.  Review of the literature”.  Journal of Oral Microbiology.  2012, 4: 
11829. 
 
Piantadosi, C.  “Carbon monoxide, reactive oxygen signaling, and oxidative stress”.  
Free Radical Biology & Medicine.  2008, 45: 562–569.   
 
Pihlstron B, Michalowicz B, Johnson N.  “Periodontal diseases”.  Lancet [serial 
online]. 2005, 366(9499): 1809-1820.  Available from: Academic Search 
Premier, Ipswich, MA. 
 
 
 53 
Raval, C., Zhong, J., Mitchell, S., Tyrrell, R.  “The role of Bach1 in ultraviolet A-
mediated human heme oxygenase 1 regulation in human skin fibroblasts”.  
Free Radical Biology & Medicine.  2012, 52: 227–236. 
 
Reichard, J., Motz, G., Puga, A.  “Heme oxygenase-1 induction by NRF2 requires 
inactivation of the transcriptional repressor BACH1”.  Nucleic Acids Research, 
2007, 35(21): 7074-7086. 
 
Rueda, B., Oliver, J., Robledo, G., Nevot, M., Balsa, A., Salcedo, D., Gay, M., Escribano, 
M., Martin, J.  “HO-1 Promoter Polymorphism Associated With Rheumatoid 
Arthritis”.  Arthritis and Rheumatology.  2007, 56(12): 3953-3958.   
 
Ryter, S., Alam, J., Choi, A.  “Heme Oxygenase-1/Carbon Monoxide: From Basic 
Science to Therapeutic Applications”.  Physiology Review.  2006, 86: 583–650. 
 
Salazar, M., Rojo, A., Velasco, D., Sagarra, R., Cuadrado, A.  “Glycogen Synthase 
Kinase-3β Inhibits the Xenobiotic and Antioxidant Cell Response by Direct 
Phosphorylation and Nuclear Exclusion of the Transcription Factor Nrf2”.  
The Journal of Biological Chemistry.  2006, 281: 14841-14851. 
 
Salinas, M., Wang, J., Sagarra, M., Martin, D., Rojo, A., Perez, J., Montellano, P., 
Cuadrado, A.  “Protein kinase Akt/PKB phosphorylates heme oxygenase-1 in 
vitro and in vivo”.  FEBS Letters. 2004, 578: 90–94. 
 
 
 54 
Sawa, T., Mounawar, M., Tatemichi, M., Gilibert, I., Katoh, T., Ohshima, H.  “Increased 
risk of gastric cancer in Japanese subjects is associated with microsatellite 
polymorphisms in the heme oxygenase-1 and the inducible nitric oxide 
synthase gene promoters”.  Cancer Letters.  2008, 78–84. 
 
Schreiber, E., Matthias, P., Muller, M.  M.  and Schaffner, W.  (1989) Rapid detection of 
octamer binding proteins with ‘mini-extracts’, prepared from a small number of 
cells.  Nucleic Acids Res.  17, 6419 
 
Stabholz, A., Soskolne, A., Shapira, L.  “Genetic and environmental risk factors for 
chronic periodontitis and aggressive periodontitis”.  Periodontology 2000.  
2010, 53: 138–153. 
 
Sunamura, M., Duda, D., Ghattas, M., Lozonschi, L., Motoi, F., Yamauchi, J., Matsuno, S., 
Shibahara, S., Abraham, N.  “Heme oxygenase-1 accelerates tumor 
angiogenesis of human pancreatic cancer”.  Angiogenesis.  2003, 6: 15–24. 
 
Terry, C M., Clikeman, J., Hoidal, J., Callahan, K.  “Effect of tumor necrosis factor-α and 
interleukin-1α on heme oxygenase-1 expression in human endothelial cells.” 
American Journal of Physiology - Heart and Circulatory Physiology.  1998, 
274(3): H883-H891. 
 
 
 
 
 55 
Thornton, R.  D., Lane, P., Borghaei, R., Pease, E., Caro, J., Mochan, E.  “Interleukin 1 
induces hypoxia-inducible factor 1 in human gingival and synovial 
fibroblasts”.  The Journal of Biological Chemistry. 2000, 350: 307-312. 
 
Tsai, J., Wang, H., Liu, P., Chen, Y., Yang, M., Chou, S., Cheng, Y., Yin, W., Hwang, J., 
Chong, I.  “High expression of heme oxygenase-1 is associated with tumor 
invasiveness and poor clinical outcome in non-small cell lung cancer 
patients”.  Cell Oncology.  2012, 35: 461–471. 
 
Vahist, Y., Uzungolu, G., Kutup, A., Gebauer, F., Koenig, A., Deutsch, L., Zehler, O., 
Busch, P., Kalinin, V., Izbicki, J., Yekebas, E.  “Heme Oxygenase-1 Germ Line 
GTn Promoter Polymorphism is an Independent Prognosticator of Tumor 
Recurrence and Survival in Pancreatic Cancer”.  Journal of Surgical Oncology.  
2011, 104: 305–311. 
 
Wagener, F., Toonen, E., Wigman, L., Fransen, J., Creemers, M., Radstake, T., Coenen, 
M., Barrera, P., Riel, P., Russel, F.  “HMOX1 Promoter Polymorphism 
Modulates the Relationship Between Disease Activity and Joint Damage in 
Rheumatoid Arthritis”.  Arthritis and Rheumatism.  2008, 58(11): 3388-3393.   
 
Xinghua Cheng, Ching-Hsin Ku, Richard C.M.  Siow, “Regulation of the Nrf2 
antioxidant pathway by microRNAs: New players in micromanaging redox 
homeostasis”.  Free Radical Biology and Medicine. 2013, 64: 4-11. 
 
 
 56 
Yet, S., Tian, R., Layne, M., Wang, Z., Maemura, K., Solovyeva, M., Ith, B., Melo, L., 
Zhang, L., Ingwall, J., Dzau, V., Lee, M., Perrella, M.  “Cardiac-Specific 
Expression of Heme Oxygenase-1 Protects Against Ischemia and Reperfusion 
Injury in Transgenic Mice”.  Circulation Research.  2001, 89: 168-173. 
 
 
 
 
 
 
 
